ONO 5334
| 中文名称 | ONO 5334 |
|---|---|
| 中文同义词 | 化合物 T16394 |
| 英文名称 | ONO 5334 |
| 英文同义词 | ONO 5334;ONO5334,ONO 5334;2H-Pyran-4-propanoic acid, β-[(cycloheptylcarbonyl)amino]tetrahydro-α-oxo-, (2Z)-2-[(4R)-3,4-dimethyl-2-thiazolidinylidene]hydrazide, (βS)- |
| CAS号 | 868273-90-9 |
| 分子式 | C21H34N4O4S |
| 分子量 | 438.59 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 868273-90-9.mol |
| 结构式 |  |
ONO 5334 性质
| 密度 | 1.36±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 形态 | 固体 |
| 酸度系数(pKa) | 7.06±0.40(Predicted) |
| 颜色 | 米白色至浅黄色 |
Ki: 0.10 nM (human cathepsin K)Ki: 0.049 nM (rabbit cathepsin K)Ki: 0.85 nM (rat cathepsin K)
ONO-5334 has inhibitory effects on human cathepsin S, human cathepsin L, human cathepsin B, porcine calpain Ι and porcine calpain II with K i values of 0.83 nM, 1.7 nM, 32 nM, 82 nM and 69 nM, respectively.ONO-5334 (0.1-1 μM; 24 hours) suppresses human osteoclast-mediated bone resorption. It potently reduces osteoclast-mediated release of CTX from bone slices as a dose dependent manner.ONO-5334 (0-10 μM; pre-treated for 16 h) inhibits antiviral activities in a discernable dose-dependent manner in Vero E6 cells by designed to capture multicycle replication, exhibiting an EC 50 value of 0.5 μM/
Cell Viability Assay
| Cell Line: | Vero E6 cells |
| Concentration: | 0.001 μM, 0.003 μM, 0.1 μM, 0.3 μM, 1 μM, 2.5 μM |
| Incubation Time: | Pre-treated for 16 h and then cultured for 24 hours |
| Result: | Inhibited SARS-COV-2 virus replication in a dose-dependent manner. |
ONO-5334 (oral administration; 0.12-15 mg/kg; single dose) can dose-dependently reduce PTHrP-induced increase in plasma calcium with significant effect (86% reduction) at 15 mg/kg. It also reduces PTHrP-induced increase in plasma CTX level in TPTX rats by 90% at 15 mg/kg.ONO-5334 (oral administration; 0.3-30 mg/kg; 7 consecutive days) at 3 mg/kg or 30 mg/kg significantly decreases CTX (a bone resorption marker) concentration. On day 7, the reduction in serum CTX concentration by ONO-5334 at 3 mg/kg and 30 mg/kg was 62% and 79%, respectively.
| Animal Model: | Monkey |
| Dosage: | 0.3 mg/kg; 3 mg/kg |
| Administration: | Oral administration; 7 consecutive days |
| Result: | Reduced bone resorption markers but not bone formation markers in normal monkeys. |